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a b s t r a c t 
The Conference on Retroviruses and Opportunistic Infections (CROI) is a major annual scientiﬁc meeting 
on HIV/AIDS and associated conditions. Tuberculosis (TB) is the number one cause of death among people 
living with HIV in developing countries and is the subject of numerous CROI presentations. This report 
will focus on the presentations at CROI that the author believes are most relevant to clinicians, the public 
health community and investigators interested in tuberculosis. 
© 2016 The Authors. Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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0  Introduction 
The Conference on Retroviruses and Opportunistic Infections
(CROI) is a major annual scientiﬁc meeting on HIV/AIDS and as-
sociated conditions. Tuberculosis (TB) is the number one cause of
death among people living with HIV in developing countries and is
the subject of numerous CROI presentations. This report focuses on
a select group of presentations at CROI 2016 on Tuberculosis. The
author is solely responsible for the selection of presentations and
the synopsis included in this report. This report is not an endorsed
activity of CROI itself. 
Poverty, HIV and TB 
The linkage between Poverty, HIV, and TB has been recognized
since the early HIV epidemic. Several of the following presenta-
tions and abstracts highlight the fact that health disparities among
the poor with HIV continue to exist, including an increased risk of
tuberculosis. 
The opening session of CROI included a session by Gerald Fried-
land from Yale, entitled Confronting HIV and TB from the Bronx, NY
to Tugela Ferry, South Africa . Dr. Friedland noted that in the 1980’s
in the poorest area of New York City, (the Bronx), Intravenous drug
use (IVDU) led to an epidemic of HIV in an area where systematic
neglect had led to overcrowding, lack of basic services, and barriers
to health care. This was fertile ground for an epidemic of multidrug∗ Corresponding author at: Mayo Clinic 200 First St. SW Rochester, MN 55905, 
United States. Tel.: + 1 507 284 9994; fax: + 1 507 2844959. 
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2405-5794/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article uesistant tuberculosis (MDR TB). Twenty years later an explosive
IV epidemic occurred among the poorest of the poor in Durban,
outh Africa and an epidemic of extremely drug resistant tubercu-
osis (XDRTB) followed. Apartheid and policies based on discrim-
nation and stigma, along with a mining industry that crowded
orkers into small living spaces fueled the epidemic. Poverty in
oth epidemics led to delays in diagnosis, challenges with appro-
riate isolation and treatment, with resultant high morbidity and
ortality. Interventions in both epidemics that used the communi-
ies’ strengths and were based on the rights of residents to public
ealth services were ultimately effective. Dr. Friedland noted that
uture public health disasters can be averted if principles of social
ustice and human rights are recognized and put into practice [1] . 
Dr. Gosawami and colleagues from Emory presented research
howing that poverty, HIV and TB remain linked in areas of the
S. They identiﬁed newly diagnosed patients with HIV infection
n 2012, and using spatial tools looked for an overlap with TB di-
gnosis and homelessness. Newly diagnosed HIV individuals who
ere “poorly linked to care” were deﬁned by absence of CD4 or
IV viral load testing over three months. They identiﬁed statis-
ically signiﬁcant spatial clustering of new diagnoses in multiple
etro Atlanta counties, smaller clusters of poorly linked individ-
als in two counties, and a poor HIV viral suppression cluster in
 single county. In the single virally unsuppressed cluster, there
ere 5 cases of virally unsuppressed persons per square mile (vs
 in other areas). Within this cluster, there was a high density
f homeless persons (60–200 homeless persons per census block).
here was overlap of TB clusters with the HIV clusters of patients
oorly linked to care including the poor viral suppression cluster.
he authors note that the spatial overlap of HIV patients poorlynder the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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a  inked to care, with TB disease and with a high density of homeless
uggests continued opportunities to partner with TB and homeless
ervice providers to improve local HIV outcomes [2] . 
Investigators in Botswana showed that with antiretroviral cov-
rage exceeding 90%, mortality due to TB in HIV-infected individ-
als substantially decreased with cancer mortality now likely ex-
eeding mortality due to TB. [3] Botswana’s results help prove that
hen resources are put in place, the linkage of HIV and TB can be
roken with a subsequent decrease in the morbidity and mortal-
ty from TB. The decline in TB related mortality is a great success
nd brings new challenges to the care of HIV-infected persons in
otswana. 
B in resource limited countries 
Tuberculosis continues to be a signiﬁcant problem in resource
imited countries, and requires unique approaches to diagnosis and
reatment. The following studies in countries as diverse as South
frica, Zambia and Haiti evaluated unique approaches to treatment
nd diagnosis. 
HPTN 071 (PopART) aims to determine the impact of a combi-
ation prevention intervention on HIV incidence. Community HIV
ealthcare workers in Zambia are responsible for the delivery of
he intervention and linkage to care. The investigators decided to
valuate if these workers could also use a simple questionnaire to
creen individuals for TB, and obtain sputum on TB suspects. 1.2%
f screened individuals (212,819 persons) had symptoms of TB and
% of these were identiﬁed as having TB. Community health care
orkers appeared with little training to be able to contribute to
ctive case ﬁnding and linkage to care [4] . 
A5274 REMEMBER study is a multi-country randomized clinical
rial comparing antiretroviral therapy (ART) + four-drug empiric TB
herapy vs. ART + isoniazid preventive therapy (IPT) in HIV-infected
ndividuals with CD4 counts < 50 cells/mm 3 . At week 48, there
as no statistical difference in mortality or AIDS progression be-
ween the empiric group and the IPT group. The empiric treatment
roup had more TB at week 48 compared to the IPT group. The in-
estigators concluded that in a population with a high burden of
B and advanced HIV, there was no demonstrable beneﬁt of em-
iric TB therapy on mortality or prevention of TB at 48 weeks [5] . 
Investigators in South Africa examined if early TB treatment of
IV infected individuals with low CD4 counts could impact mor-
ality and hospitalization. They randomized primary care clinics
o either an intervention arm where nurses categorized ART naïve
IV infected individuals with CD4 counts < 150 as being high risk,
oderate risk or low risk for TB based on clinical criteria. High
isk individuals were immediately started on antituberculous treat-
ent (ATT), medium risk individuals had additional TB investiga-
ions and reevaluation in one week and low risk individuals were
tarted on ART. Mortality was approximately 20% in both arms and
his strategy did not reduce mortality or the risk of hospitalization
ver 6 months. Additional work is needed to identify strategies to
educe early mortality among persons with advanced HIV at high
isk for TB [6] . 
Investigators in Haiti evaluated the diagnostic yield of an inte-
rated TB/HIV symptom screen and the added value of the Gen-
Xpert MTB/Rif (Xpert) testing for patients at the time of HIV
esting. The Xpert test is an automated diagnostic cartridge based
ucleic acid ampliﬁcation test (NAAT) that can identify Mycobac-
erium tuberculosis DNA and resistance to rifampicin. Patients were
creened for cough at the time of HIV testing, and those with
ough received evaluation for active TB by chest x-ray (CXR), acid
ast bacilli smear, and Xpert testing. 30,316 patients were tested
or HIV and screened for cough and 11% tested HIV-positive. 33%
f the HIV-infected patients reported cough, and 23% were diag-
osed with TB. 20% HIV-negative patients also reported cough, and2% were diagnosed with TB. 1469 patients were diagnosed with
B at the time of HIV testing, and 228 patients (16%) were smear-
egative but Xpert positive. The Xpert sputum testing allowed for
arly identiﬁcation of 16% of patients with TB that would other-
ise not have been diagnosed until cultures returned positive. The
ost effectiveness of sputum Xpert should be further studied in ad-
itional settings [7] . 
A small study conducted in Kenya looked at the sensitivity of
tool Xpert and Urine lateral ﬂow lipoarabinomannan (LAM) when
ompared to the combined gold standard of sputum or gastric cul-
ure and sputum or gastric Xpert for tuberculosis. 9 children were
ound to have microbiologically conﬁrmed TB, 6 of the 9 children
ere positive by stool Xpert for a sensitivity of 67%, and 130 were
lassiﬁed as negative for a speciﬁcity of 99%. Among 114 children
ith a urine sample, LAM identiﬁed 3 of 6 conﬁrmed TB cases for
ensitivity of 50% and classiﬁed 96 of 108 children without con-
rmed TB as negative. Stool Xpert may be useful addition to test-
ng for tuberculosis in children when sputum or gastrics samples
re challenging to obtain [8] . 
Investigators from India noted that TB is more likely to occur
ostpartum than at any other time in a woman’s life and exam-
ned if immune changes in pregnancy and postpartum affect the
nterferon-gamma (IFN-g) response to M. tuberculosis antigens in
IV infected and uninfected women. They screened women for la-
ent TB with an IFN-g release assay (QuantiFERON Gold in tube,
QGIT)) during 2nd/3rd trimester of pregnancy, at delivery and 3
onths postpartum. IFN-g reached a nadir for both HIV-infected
nd uninfected women at delivery; and HIV-infected women had
 larger decrease in IFN-g. HIV uninfected women had a signiﬁ-
ant increase in IFN-g production postpartum while HIV infected
omen did not. The authors speculate that lower IFN-g production
uring pregnancy, may facilitate progression to active TB, despite
ymptoms not appearing until postpartum, when IFN-g production
ncreases again. Clinicians using QGIT for diagnosing latent TB dur-
ng pregnancy need to be aware of the lower sensitivity of this test
uring pregnancy [9] . 
A study from Botswana, a country that has been remarkably
uccessful in rolling out ART, found an overall MDR TB treatment
uccess rate of 74% for HIV infected individuals compared to 57%
reatment success rates in the pre-ART era. Risk of dying decreased
rom 33% to 13% as CD4 at the time of diagnosis increased from
 100 to > 350 cells/mm 3 . MDR TB treatment success rates in-
reased from 67% to 86% as CD4 counts increased from < 100 to
 350 cells/mm 3 at the time of diagnosis. The importance of early
iagnosis and treatment of HIV is once again highlighted [10] . 
ew treatments for TB 
New drugs, better tolerated drugs, and shorter effective treat-
ent programs are needed not only for MDR and XDR TB but
ould be beneﬁcial for pansusceptible TB. Patients often don’t
omplete recommended treatment courses for both active and la-
ent TB. Signiﬁcant resources are required to ensure completion of
urrent treatment programs. Two presentations discussed the pos-
ibility of using available drugs in new ways. 
Eric Rubin from the Harvard School of Public Health discussed
n his plenary session theories on the pathophysiology of latent tu-
erculosis; including the long held belief that in latent infection
he tuberculosis bacteria are dormant and they must “wake up”
o cause active symptomatic infection. He presented an alternative
ypothesis of latent tuberculosis and active tuberculosis as a spec-
rum of disease related to bacterial burden. The higher the bacte-
ial load the more likely one is to become symptomatic. Dr. Rubin
oted that not only is there work in primate models supporting
his hypothesis, but latent tuberculosis can be treated with isoni-
zid (INH) alone and INH kills replicating bacteria. He proposed
30 M.J. Kasten / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 4 (2016) 28–32 
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v  that we may be able to do better with our current drugs if we use
them in new ways in light of this evidence and fewer patients will
ask “Why do I have to take so many pills?” the title of his talk [11] .
The potential of beta lactam drugs which have been generally
believed to be ineffective against M. tuberculosis, as antituber-
culous agents was presented by Andreas Diacon of Stellenbosch
University. Groups of 15 patients with newly diagnosed smear
positive pansusceptible pulmonary tuberculosis were treated with
meropenem and amoxicillin/clavulanic acid (A/CA), or faropenem
(an oral carbapenem) and A/CA or standard antituberculosis treat-
ment for two weeks. The mycobacterial sputum load was sig-
niﬁcantly decreased with the meropenem, A/CA treatment and
with standard treatment but not with faropenem, A/CA. The
carbapenem/beta-lactam treatments were well tolerated, however
intermittent diarrhea was noted by > 50% of patients in both
carbapenem groups. The combination of intravenous meropenem
and oral A/CA in this study had similar mycobacterial activity as
the regimen of rifampin (10 mg/kg), pyrazinamide and bedaquiline
over the ﬁrst 2 weeks of treatment. Where IV treatment is fea-
sible and treatment options are limited, IV meropenem combined
with oral A/CA should be considered. An oral bioavailable carbape-
nam combined with a beta lactamase inhibitor should be further
explored as a tuberculosis treatment [12] . 
TB and antiretroviral therapy 
Patients with TB and HIV are usually chronically ill and the im-
pact of each illness on the other is often profound. Additional un-
derstanding of the impact each illness has on the other would be
clinically helpful. 
Investigators from Switzerland examined the CD4 cell and HIV-
RNA viral load changes in 113,0 0 0 HIV infected ART naive European
patients with and without a history of TB after starting ART. They
found CD4 recovery to be slower in patients with active or recent
tuberculosis and HIV viral load decline slower for patients with ac-
tive tuberculosis during the ﬁrst 6 months of ART. They did not
comment on the possibility of drug–drug interactions contributing
to this ﬁnding. They found these unfavorable effects to be more
pronounced among immigrants from high-incidence TB countries.
The reasons for slower CD4 recovery and viral load decline with
ART in HIV individuals with active or recent TB requires further
investigation [13] . 
Pharmokinetics in HIV and drug–drug interactions 
Interactions between HIV medications and antituberculosis
medications are common and often complicate treatment. The fol-
lowing studies evaluated a variety of pharmokinetic issues and
drug-drug interactions between ARTs and antituberculosis medica-
tions. 
A particularly problematic drug–drug interaction occurs with ri-
fampin and protease inhibitors. Cobicistat and ritonavir are both
used to boost levels of protease inhibitors through inhibition of
cytochrome P450 3A and 2D6. They are not however completely
interchangeable and a team of investigators from the University
of Liverpool found that although ritonavir and cobicistat both at-
tenuated the intrinsic clearance of darunavir induced by rifampin,
ritonavir reversed rifampin induction more strongly than cobicis-
tat. Cobicistat is likely to be used increasingly frequently in pa-
tients with HIV. Clinicians need to remember that despite co-
bicistat’s mechanism of action being similar to ritonavir’s; dosage
adjustment for impacted medications is likely to be different than
the adjustment for ritonavir [14] . 
An Indian study compared pharmokinetics of antituberculosis
drugs in children coinfected with HIV and TB, to children infected
only with TB. HIV infected children were treated with efavirenznd lamivudine, and either stavudine, zidovudine, tenofovir or aba-
avir. They found a lower C max of INH and Rifampin in HIV/TB
oinfected children and lower AUC of rifampin. Unfavorable out-
omes were associated with a lower body mass index, smaller
ead circumference; lower C max and AUC of rifampin and pyraz-
namide. HIV/TB coinfected children were signiﬁcantly more likely
o be underweight, have a lower albumin and smaller head circum-
erences that children infected with only TB. It is unclear from this
tudy if the lower drug levels in HIV infected children is related to
oorer nutritional status, drug-drug interactions or a combination
15] . 
Investigators in Zambia sought to determine an appropriate
favirenz (EFV) dose for HIV infected infants and children between
 and 36 months being treated for tuberculosis. Additionally wide
ariations in EFV plasma concentrations have been described in
hildren with a single nucleotide polymorphism in the CYP 2B6
ene. The CYP 2B6 516 TT (mutant) genotype is associated with de-
reased clearance and greater EFV plasma exposure. Ampliﬁed dos-
ng ( ∼65 mg/kg) in co-infected HIV + /TB + children with nonmutant
YP2B6 GG/GT genotype produced therapeutic EFV concentrations
n 6/8 children < 2 years. A lower dose is predicted to be needed
or children in this age group with slow CYP2B6 metabolism (mu-
ant CYP2B6 genotype) who are being treated for tuberculosis. The
nvestigators conclude that pre-treatment genotyping will allow for
ppropriate EFV dosing with optimal exposure of EFV in HIV + /TB +
hildren < 2 years of age [16] . 
An Indian study retrospectively compared those treated with an
tazanavir/ritonavir (ATV/r) ART regimen plus a 150 mg daily or
hrice weekly rifabutin-containing TB regimen with those treated
ith a non-nucleoside reverse transcriptase inhibitor (NNRTI)-
ased ART regimen in conjunction with a daily rifampicin con-
aining TB regimen. Over 40 0 0 HIV/TB infected patients were eval-
ated with 3740 having been treated with an NNRTI-based ART
egimen and a rifampicin TB regimen and 292 an ATV/r-based
RT regimen with a rifabutin TB regimen. Those in the ATV/r-
ifabutin group were less likely to develop relapsed/recurrent TB
nd had lower all-cause mortality compared to those in the NNRTI-
ifampicin group. In addition, those in the Rifabutin group that
eceived intermittent rifabutin had lower clinical cure rates com-
ared to those who received daily rifabutin, although there was
o statistically signiﬁcant difference in rate of relapse/recurrent TB
nd all-cause mortality between these two subgroups. A limitation
f this study is its retrospective nature and the inclusion of pa-
ients diagnosed over a wide time period (between 1996 and 2014)
hen other changes in health care likely occurred, that may have
nﬂuenced the results. This large, retrospective study observed that
ntituberculosis treatment with rifabutin was overall effective, and
aily rifabutin dosing may be more effective than intermittently-
osed rifabutin for the treatment of uncomplicated TB in HIV/TB
o-infected individuals on a boosted PI-based ART regimen [17] . 
Doravirine a novel NNRTI developed by Merck is primarily me-
abolized by oxidation via Cytochrome P450 3A4 (CYP3A4) and
ifamycins are inducers of this cytochrome. Rifampin has been
hown to signiﬁcantly decrease doavirine levels and should not
e coadministered with doravirine. Investigators associated with
erck studied how rifabutin which is a more moderate inducer
f CYP3A4 affected doravirine pharmokinetics. Rifabutin decreased
oravirine AUC by 50%. The investigators speculate that increas-
ng the dose of doravirine may allow for use of doravirine with
ifabutin but further study is required [18] . 
mmune reconstitution inﬂammatory syndrome (IRIS) 
Paradoxical inﬂammatory syndromes have been recognized in
atients being treated for TB long before the HIV epidemic. Indi-
iduals coinfected with TB and HIV are at high risk of developing
M.J. Kasten / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 4 (2016) 28–32 31 
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 his syndrome called IRIS. IRIS can occur in HIV-infected individ-
als not only during active treatment of TB but with treatment of
ther infections and with ART alone. Two studies attempted to bet-
er understand the immunology behind this syndrome. 
Investigators at an HIV clinic in Cape Town South Africa investi-
ated the hypothesis that matrix metalloproteinases (MMPs), pre-
iously implicated in TB tissue destruction, were associated with
B-IRIS. They recruited 49 HIV antiretroviral naïve patients with
D4 counts < 200 cells/mm 3 , presenting with pulmonary tubercu-
osis. Twenty nine developed TB-IRIS after a median of 14 days of
RT. Plasma MMPs, most signiﬁcantly MMP-8, were elevated in TB-
RIS patients with the greatest difference observed at the time TB
reatment was initiated, followed by 2 weeks of antiretroviral ther-
py. These ﬁndings implicate systemic MMP dysregulation in TB-
RIS pathophysiology. Neutrophil-derived MMP-8 may be a predic-
ive and diagnostic marker for TB-IRIS and potentially a therapeutic
arget [19] . 
Another group of investigators from Cape Town investigated the
mmunologic basis of Bacillus Calmette–Guérin vaccine (BCG) as-
ociated IRIS in HIV infected infants and children < 6 years old
nitiating ART. 41% of infants ( < 6 months old) developed IRIS fol-
owing initiation of ART with 21 experiencing BCG IRIS related
vents 2-8 weeks after ART initiation. Cases were compared with
1 non-IRIS controls matched by age, nadir CD4, frequency and
uration of ART at time of IRIS diagnosis. The investigators com-
ared a number of immune cells between cases and controls. At
ntry, compared to controls, cases exhibited reduced absolute CD3
nd CD4 T cell counts, higher frequencies of CD14 + CD16 + inﬂam-
atory monocytes and NK cells; lower frequencies of BCG-speciﬁc
L22 + CD4 + T cells and gag-speciﬁc CD4 T cells expressing IFN-g,
umor necrosis factor alpha, interleukin 10, and CD154. Signiﬁcant
ncrease in CD4 absolute counts was evident in cases but not con-
rols. A dramatic immune reconstitution of BCG-speciﬁc Th1 cells
as observed at IRIS diagnosis, compared to control samples. By
ontrast, reconstitution of gag-speciﬁc CD4 T cells was not differ-
nt across groups. At time of IRIS diagnosis frequencies of NK cells
emained higher in cases compared to controls. The investigators
onclude that these ﬁndings imply that underlying immune de-
ciency and lack of BCG-speciﬁc Th22 cells coupled with inﬂam-
ation involving monocytes contributes to the pathophysiology of
CG IRIS [20] . 
ransmission 
Understanding TB transmission is an important public health
oncern and key to controlling and preventing TB outbreaks.
he ﬁnal two studies in this report address this important
opic. 
Investigators in Switzerland compared estimations of trans-
ission among immigrants with TB, HIV infected individuals
nd Swiss borne individuals with tuberculosis using traditional
nd whole gene sequencing (WGS). Using traditional genotyp-
ng they identiﬁed 35 clusters of patients suggesting active
ransmission. Only 17/35 (49%) traditionally-deﬁned transmis-
ion clusters were conﬁrmed “true” clusters by WGS; the other
8 clusters contained pairs separated by > 12 single nucleotide
olymorphisms. Traditional genotyping methods led to an overes-
imation of recent transmission among foreign-born TB patients in
his study [21] . 
A South African study used social networking analysis to char-
cterize patterns of transmission of extensively drug resistant TB
XDR TB) in a high HIV prevalence area in KwaZulu-Natal province.
hey reported having previously demonstrated that up to 83% of
DR TB cases are genotypically-clustered, suggesting person-to-
erson transmission is driving the XDR TB epidemic in this high-
IV prevalence setting rather than poor TB treatment with devel-pment of resistance. In the current study, they employed social
etwork analysis to further characterize patterns of transmission.
atients with XDR TB were interviewed at the time of diagnosis
bout their social networks at home, work, and other community
ocations, as well as about hospitalizations in the ﬁve years preced-
ng their XDR TB diagnosis. Epidemiologic links were identiﬁed for
87 (71%) patients. 83 (21%) patients were linked as social network
ontacts; of these, 92% lived in the same home, and 267 (66%) pa-
ients overlapped with other XDR TB patients in the hospital. There
ere 63 (16%) patients with both hospital and social network links
o other XDR TB patients. The authors conclude that the XDR TB
pidemic in this high HIV prevalence setting is being driven by di-
ect transmission of drug-resistant TB strains in both hospitals and
ouseholds [22] . 
ummary 
The TB presentations at CROI struck both hopeful and cau-
ionary notes. Progress has been made in controlling HIV-TB epi-
emics when resources that engage the affected population are
ut in place. Recurrent epidemics are likely to occur in disenfran-
hised populations with barriers to receiving health care. The high
ercentage of XDR cases that appear to be due to person-person
ransmission emphasizes the importance of early identiﬁcation of
ases and appropriate isolation. Public health oﬃcials need to con-
inually evaluate the challenges and strengths in their respective
ommunities, and formulate strategies that will not only be able
o address epidemics but are proactive and will prevent their oc-
urrence. New drugs, new studies of old drugs and new diagnostics
emain important areas of study if we hope to avoid epidemics of
DR and XDR TB in the future. 
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